4.8 Article

Self-assembled polydopamine nanoparticles improve treatment in Parkinson's disease model mice and suppress dopamine-induced dyskinesia

Journal

ACTA BIOMATERIALIA
Volume 109, Issue -, Pages 220-228

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.actbio.2020.03.021

Keywords

Self-assembled drug; Poly(L-DOPA); Parkinson's disease; Polymer micelle-prodrug; Dopamine delivery; BBB

Funding

  1. Ministry of Education, Culture, Sports, Science, and Technology (MEXT) [18H04160]
  2. [108.05-2017.327]
  3. Grants-in-Aid for Scientific Research [18H04160] Funding Source: KAKEN

Ask authors/readers for more resources

Although Levodopa (L-DOPA), a dopamine precursor, exhibits a high risk of dyskinesia, it remains the primary treatment in Parkinson's disease (PD), a progressive neurodegenerative disorder. In this study, we designed poly(L-DOPA)-based self-assembled nanodrug (Nano(DOPA)) from amphiphilic block copolymer possessing poly(L-DOPA(OAc)(2)), which is a precursor of L-DOPA as a hydrophobic segment, for treatment in a PD model mouse. Under physiological enzyme treatment, the poly(L-DOPA(OAc)(2)) in the block copolymer was hydrolyzed to liberate L-DOPA gradually. Using the MPTP-induced PD mouse model, we observed that mice treated with Nano(DOPA) demonstrated a significant improvement of PD symptoms compared to the L-DOPA treatment. Interestingly, the Nano(DOPA) treatment did not cause the dyskinesia symptoms, which was clearly observed in the L-DOPA-treated mice. Furthermore, Nano(DOPA) exhibited remarkably lower toxicity in vitro compared to L-DOPA, in addition with no noticeable Nano(DOPA) toxicity observed in the treated mice. These results suggested that self-assembled Nano(DOPA) is a promising therapeutic in the treatment of PD. Statement of Significance In this study, we proposed a therapeutic approach for the effective treatment of Parkinson's disease (PD) using newly designed poly(L-DOPA)-based self-assembled nanodrug (Nano(DOPA)) prepared from amphiphilic block copolymers possessing poly(L-DOPA(OAc)(2)), which is a precursor of L-DOPA as a hydrophobic segment, for treatment in a PD model mouse. Under physiological enzyme treatments,Nano(DOPA) was hydrolyzed to liberate L-DOPA gradually, improving the pharmacokinetic value of L-DOPA. The mice treated with Nano(DOPA) significantly improved PD symptoms compared to the L-DOPA treatment in a neurotoxin-induced PD mouse model. Interestingly, Nano(DOPA) treatment did not cause dyskinesia symptoms, which was observed in the L-DOPA-treated mice. The obtained results in this study suggested that self-assembled Nano(DOPA) is a promising therapeutic in the treatment of PD. (C) 2020 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available